Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Data Safety Monitoring Board gives OK to Prana for Imagine Trial for Alzheimer’s

9:07 am by | 4 Comments

Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today reported that it had received a recommendation from the Data Safety Monitoring Board (DSMB) that the IMAGINE trial for Alzheimer's disease should continue as planned based on the initial review of clinical data. The DSMB is an independent group of experts who review the accumulated safety data in ongoing clinical trials, in order to safeguard the interests and safety of participating and future patients. The DSMB considers study-specific data as well as relevant background knowledge about the disease, test agent, or patient population under study.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Paul Quintaro,

Visit website | More posts by Author

3 comments
Agriculture Website Designers
Agriculture Website Designers like.author.displayName like.author.displayName like.author.displayName like.author.displayName 4 Like

The DSMB considers study-specific data as well as relevant background knowledge about the disease, test agent, or patient population under study.

David Greene
David Greene

The DSMB is an independent group of experts who review the accumulated safety data in ongoing clinical trials, in order to safeguard the interests and safety of participating and future patients.

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement